<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389465</url>
  </required_header>
  <id_info>
    <org_study_id>5R01MH098260-02</org_study_id>
    <nct_id>NCT02389465</nct_id>
  </id_info>
  <brief_title>Late-Life Stress and Inflammation</brief_title>
  <acronym>S&amp;I</acronym>
  <official_title>Stress and Inflammation in the Pathophysiology of Late Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that&#xD;
      there is a link between depression and inflammatory disease. This study investigates the&#xD;
      relationship between inflammation in the brain and depression. Comparing biological and&#xD;
      psychological differences in depressed and non-depressed people allows researchers to find&#xD;
      better ways to treat and prevent depression. All participants will have: neuropsychological&#xD;
      tests, an EKG, a spinal tap, a blood draw, and, if depressed, given either an antidepressant&#xD;
      coupled with an anti-inflammatory medication or an anti-depressant coupled with a placebo for&#xD;
      six weeks. The investigators are trying to correlate brain function with depression levels&#xD;
      and biomarkers from the blood and spinal fluid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine Levels</measure>
    <time_frame>up to week 6</time_frame>
    <description>Blood and cerebrospinal fluid will be analyzed for levels of cytokines (inflammatory proteins) including IL-6 and IL-10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>up to week 6</time_frame>
    <description>This depression rating scale will be used to determine clinical outcome for depressed participants.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Depression</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm is for participants who are not depressed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental - treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram + Celecoxib</intervention_name>
    <description>Participants will receive celecoxib in addition to escitalopram</description>
    <arm_group_label>Experimental - treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram + Placebo</intervention_name>
    <description>Participants will receive a placebo in addition to escitalopram.</description>
    <arm_group_label>Experimental - treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80, male or female, any race;&#xD;
&#xD;
          2. Absence of clinical dementia&#xD;
&#xD;
          3. English speaking&#xD;
&#xD;
          4. Blood pressure not exceeding 150/90 mmHg, treated or untreated&#xD;
&#xD;
          5. Weight greater than 110 lbs&#xD;
&#xD;
          6. Normal result on liver-function test&#xD;
&#xD;
          7. No history of ulcer disease or GI bleeding&#xD;
&#xD;
          8. No renal insufficiency&#xD;
&#xD;
        Additional Inclusion Criteria for Depressed Participants:&#xD;
&#xD;
          1. DSM-IV criteria for Major Depressive Disorder&#xD;
&#xD;
          2. HAM-D greater than 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history of relevant severe drug allergy or hypersensitivity (e.g. to Citalopram&#xD;
             or Escitalopram, and/or to celecoxib, aspirin, or other NSAIDs only for Phase 2; known&#xD;
             demonstration of allergic-type reactions to sulfonamides);&#xD;
&#xD;
          2. Does not speak English;&#xD;
&#xD;
          3. Cannot give informed consent;&#xD;
&#xD;
          4. MRI contraindications (e.g., foreign metallic implants, pacemaker);&#xD;
&#xD;
          5. Known primary neurological disorders, such as Parkinson's disease, Alzheimer's&#xD;
             disease, traumatic brain injury, cognitive impairment or dementia,&#xD;
&#xD;
          6. Known severe inflammatory disease such as systemic lupus erythematosis, known&#xD;
             autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis; Screen + for&#xD;
             RF, ANA, HIV, Hepatitis B or C.&#xD;
&#xD;
          7. Clinical Dementia Rating Scale score greater than 0;&#xD;
&#xD;
          8. Diagnosis of a chronic psychiatric illness other than MDD at the discretion of the&#xD;
             study doctor;&#xD;
&#xD;
          9. Significant handicaps (e.g. uncorrected hearing or visual impairment, mental&#xD;
             retardation) that would interfere with testing;&#xD;
&#xD;
         10. Bleeding diathesis;&#xD;
&#xD;
         11. Severe Medical problem, which in the opinion of the investigator would pose a safety&#xD;
             risk to the subject;&#xD;
&#xD;
         12. Clinically significant cardiovascular disease that will be assessed on a case-by-case&#xD;
             basis. Clinically significant cardiovascular disease usually includes one or more of&#xD;
             the following: cardiac surgery or myocardial infarction within the last 4 weeks;&#xD;
             unstable angina; acute decompensated congestive heart failure or class IV heart&#xD;
             failure; current significant cardiac arrhythmia or conduction disturbance,&#xD;
             particularly those resulting in ventricular fibrillation, or causing syncope or near&#xD;
             syncope; uncontrolled high blood pressure; QTc greater than 450msec (by history for&#xD;
             subjects with cardiac disease); documented prior stroke;&#xD;
&#xD;
         13. Clinically significant abnormalities on EKG. Primary AV block or Right bundle branch&#xD;
             block are not necessarily exclusionary;&#xD;
&#xD;
         14. Current diagnosis of cancer&#xD;
&#xD;
         15. Current diagnosis of HIV, active Hepatitis B and/or Hepatitis C&#xD;
&#xD;
         16. Use of an Investigational medicine within the past 30 days;&#xD;
&#xD;
         17. Use of Coumadin, Warfarin within the past 2 months;&#xD;
&#xD;
         18. Current treatment with psychotropic drugs or drugs that affect the CNS such as&#xD;
             beta-blockers, mood stabilizers, antipsychotics, steroids or non-steroidal&#xD;
             anti-inflammatory medications or other antidepressants. No subjects will be included&#xD;
             in the study unless they have been off all psychotropics for at least 3 weeks, except&#xD;
             in the case of fluoxetine, where 5 weeks off treatment will be required;&#xD;
&#xD;
         19. Current alcohol or substance abuse disorder, schizophrenia or other psychotic&#xD;
             disorder, bipolar disorder, or current OCD;&#xD;
&#xD;
         20. Abnormal liver-function test&#xD;
&#xD;
         21. History of ulcer disease, Chron's disease, GI bleeding or anemia&#xD;
&#xD;
         22. Weight less than 110 lbs&#xD;
&#xD;
         23. Renal insufficiency&#xD;
&#xD;
         24. Any other factor that in the investigator's judgment may affect patient safety or&#xD;
             compliance (e.g. distance greater than 100 miles from this facility);&#xD;
&#xD;
        Additional Exclusion Criteria for Depressed Subjects:&#xD;
&#xD;
        1) Active suicidality or current suicidal risk as determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvette Sheline</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Geriatric</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

